Bench to bedside: research influencing clinical practice in breast cancer
Based on recent evidence derived from clinical trials and translational research, breast cancer pathology has witnessed a rapid increase in the utilization of predictive markers, companion diagnostics and molecular testing for tailored management of patients with breast cancer. New diagnostic entities with specific molecular phenotypes have also been included in the classification of breast cancer. Genomic assays including Oncotype DX ®21-gene Recurrence Score (RS), Prosigna and EndoPredict are currently used in routine practice to guide adjuvant/neoadjuvant therapy.
Source: Diagnostic Histopathology - Category: Pathology Authors: Abeer M Shaaban, Emily C Shaw Tags: Mini-symposium: Research influencing clinical practice Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Neoadjuvant Therapy | Pathology